Presenter: Dr. Jason Weatherald
Moderator: Dr. Lisa Mielniczuk

Pulmonary hypertension (PH) results in progressive symptoms and a risk of right heart failure. Therapeutic studies have largely focussed on exercise capacity, hemodynamics and long-term morbidity outcomes. Quality of life (QoL) is an important outcome for patients with PH but measurement in clinical practice can be cumbersome. Recently, there has been a focus on disease-specific patient reported quality of life measurements to guide clinical decision making. After this symposium, attendees will be able to use simple and validated tools to measure quality of life for patients with PH, understand how quality of life relates to other clinical variables and can be impacted by therapies, and appreciate how to integrate quality of life tools with other risk-based clinical decision tools.

Learning objectives
At the end of this presentation, attendees will be able to:

  • Identify the current approach to patient management and associated risk parameters;
  • Describe the QoL indicators commonly used in PH; and
  • Discuss the latest evidence for clinical decision-making strategies and potential impact on QoL.

CanMEDs Roles Addressed:
Medical Expert, Health Advocate

 

This session is co-developed by the Canadian Thoracic Society and Janssen and is planned to achieve scientific integrity, objectivity and balance.